The future role of anti-tumour necrosis factor (TNF) products in the treatment of rheumatoid arthritis

Drugs

Volumn 55, Issue 5, 1998, Pages 613-620

  Camussi, Giovanni ^a,b   Lupia, Enrico ^a  

^a UNIVERSITY OF PAVIA   (Italy)

^b MOLINETTE HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID A PROTEIN; C REACTIVE PROTEIN; HEMOGLOBIN; MONOCLONAL ANTIBODY; RHEUMATOID FACTOR; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; TUMOR NECROSIS FACTOR RECEPTOR;

ARTICLE; ERYTHROCYTE SEDIMENTATION RATE; INFLAMMATORY CELL; JOINT DESTRUCTION; LEUKOCYTE COUNT; MEDIATOR; RHEUMATOID ARTHRITIS; SYNOVITIS; THROMBOCYTE COUNT;

ANIMALS; ANTIBODIES, MONOCLONAL; ARTHRITIS, RHEUMATOID; HUMANS; MICE; RANDOMIZED CONTROLLED TRIALS; RECEPTORS, TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR-ALPHA;

MUS MUSCULUS;

EID: 0031946293     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199855050-00001     Document Type: Article

References (52)

1. Silman AJ, Hockberg MC. Epidemiology of rheumatic diseases. Oxford: Oxford University Press. 1993
2. Erbardt CC, Mumford PA, Venables PJ, et al. Factors predicting a poor life prognosis in rheumatoid arthritis: an eight year prospective study. Ann Rheum Dis 1989; 48: 7-13
3. Feldmann M, Brennan FM, Maini RN. Role of cytokines in rheumatoid arthritis. Ann Rev Immunol 1996; 14: 397-440
4. Feldmann M, Elliott MJ, Woody JN, et al. Anti-tumor necrosis factor-α therapy of rheumatoid arthritis. Adv Immunol 1997; 64: 283-350
5. Tetta C, Camussi G, Modena V, et al. Tumor necrosis factor in serum and synovial fluid of patients with active and severe rheumatoid arthritis. Ann Rheum Dis 1990; 49: 665-7
6. Brennan FN, Gibbons DL, Mitehell T, et al. Enhanced expression of tumor necrosis factor receptor mRNA and protein in mononuclear cells isolated from rheumatoid arthritis synovial joints. Eur J Immunol 1992; 22: 1907-12
7. Hushy G, Williams RC. Synovial localization of tumor necrosis factor in patients with rheumatoid arthritis. J Autoimmun 1988; 1: 363-71
8. Lupia E, Montrucchio G, Battaglia E, et al. Role of tumor necrosis factor-α and platelet-activating factor in neoangiogenesis induced by synovial fluids of patients with rheumatoid arthmis. Eur J Immunol 1996; 26: 1690-4
9. Dayer JM, Beutler B, Cerami A. Cachectin/tumor necrosis factor stimulates collagenase and prostaglandin E production by human synovial cells and dermal fibroblasts. J Exp Med 1985; 162: 2163-8
10. Deleuran BMW, Chu CQ, Field M, et al. Localization of tumor necrosis factor receptors in the synovial tissue and cartilage-pannus junction in patients with rheumatoid arthritis: implications for local actions of tumor necrosis factor α. Arthritis Rheum 1992; 35: 1170-8
11. Keffer J, Probert L, Cazlaris H, et al. Transgenic mice expressing human tumor necrosis factor: a predictive genetic model of arthritis. EMBO J 1991; 10: 4025-31
12. Piquet PF, Grau GE, Vesin C, et al. Evolution of collagen arthritis in mice is arrested by treatment with anti-tumor necrosis factor (TNF) antibody or a recombinant soluble TN F receptor. Immunology 1992; 77: 510-4
13. Wooley PH, Dutcher J, Widmer MB, et al. Influence of a recombinant human soluble tumor necrosis factor receptor Fc fusion protein on type II collagen-induced arthritis in mice. J Immunol 1993; 151: 6602-7
14. Firestein GS, Zvaifler NJ. Anticytokine therapy in rheumatoid arthritis. N Engl J Med 1997; 337: 195-7
15. Knight DM, Trinh H, Le J, et al. Construction and initial characterization of a mouse-human chimeric anti-TNF antibody. Mol Immunol 1993; 30: 1443-53
16. Elliott MJ, Maini RN, Feldmann M, et al. Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor-α (cA2) versus placebo in rheumatoid arthritis. Lancet 1994; 344: 1105-10
17. Paulus HE, Egger MJ, Ward JR, et al. Analysis of improvement in individual rheumatoid arthritis patients treated with disease-modifying antirheumatic drugs, based on the findings in patients treated with placebo. Arthritis Rheum 1990; 33: 477-84
18. Elliott MJ, Maini RN, Feldmann M, et al. Repeated therapy with monoclonal antibody to tumor necrosis factor-α (cA2) in patients with rheumatoid arthritis. Lancet 1994; 344: 1125-8
19. Elliott MJ, Maini RN, Feldmann M, et al. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor-α. Arthritis Rheum 1993; 36: 1681-90
20. Lorenz H-M, Antoni C, Valerius T, et al. In vivo blockade of TNF-α by intravenous infusion of a chimeric monoclonal TNF-α antibody in patients with rheumatoid arthritis: short term cellular and molecular effects. J Immunol 1996; 156: 1646-53
21. Tak PP, Taylor PC, Breedveld FC, et al. Decrease in cellularity and expression of adhesion molecules by anti-tumor necrosis factor-α monoclonal antibody treatment in patients with rheumatoid arthritis. Arthritis Rheum 1996; 39: 1077-81
22. Paleolog EM, Hunt M, Elliott MJ, et al. Deactivation of vascular endothelium by monoclonal anti-tumor necrosis factor-α antibody in rheumatoid arthritis. Arthritis Rheum 1996; 39: 1082-91
23. Rankin ECC, Choy EHS, Kassimos D, et al. The therapeutic effects of an engineered human anti-tumor necrosis factor alpha antibody (CDP571) in rheumatoid arthritis. Br J Rheumatol 1995; 34: 334-42
24. Moreland LW, Margolies G, Heck Jr LW, et al. Recombinant soluble tumor necrosis factor receptor (p80) fusion protein: toxicity and dose finding trial in refractory rheumatoid arthritis. J Rheumatol 1996; 23: 1849-55
25. Moreland LW, Baumgartner SW, Schiff MH, et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med 1997; 337: 141-7
26. Epstein WV, Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor-Fc fusion protein. N Engl J Med 1997; 337: 337-8
27. Williams RO, Mason LJ, Feldmann M, et al. Synergy between anti-CD4 and anti-tumor necrosis factor in the amelioration of established collagen-induced arthritis. Proc Natl Acad Sci USA 1994; 91: 2762-6
28. Linsley PS, Wallace PM, Johnson J, et al. Immunosuppression in vivo by a soluble form of the CTLA-4 T cell activation molecule. Science 1992; 257: 792-5
29. Biancone L, Andres G, Ahn A, et al. Inhibition of the CD40-CD40 ligand pathway prevents murine membranous glomerulonephritis. Kidney Int 1995; 48: 458-68
30. Mannik M, Wener M. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor-Fc fusion protein. N Engl J Med 1997; 337: 338
31. Gay S, Gay RE, Koopman WJ. Molecular and cellular mechanisms of joint destruction in rheumatoid arthritis: two cellular mechanisms explain joint destruction. Ann Rheum Dis 1993; 52: S39-47
32. Muller-Ladner U, Kriegsniann J, Franklin BN, et al. Synovial fibroblasts of patients with rheumatoid arthritis attach to and invade normal human cartilage when engrafted into SCID mice. Am J Pathol 1996; 149: 1607-15
33. Russell D, Tucker K, Kohno H, et al. Inhibition of tumor necrosis factor is effective alone or in combination with inhibition of interleukin-1 in reducing joint swelling in rodent bacterial cell wall-induced arthritis. Arthritis Rheum 1994; 37 Suppl. 9: 279
34. Joyce DA, Gibbons DP, Green P, et al. Two inhibitors of proinflammatory cytokine release, interleukin-10 and interleukin-4, have contrasting effects on release of soluble p75 tumor necrosis factor receptor by cultured monocytes. Eur J Immunol 1994; 24: 2699-705
35. Joosten LA, Lubberts E, Durez P, et al. Role of interleukin-4 and interleukin-10 in murine collagen-induced arthritis: protective effect of interleukin-4 and interleukin-10 treatment on cartilage destruction. Arthritis Rheum 1997; 40: 249-60
36. Le CH, Nicolson G, Morales A, et al. Suppression of collagen-induced arthritis through adenovirus-mediated transfer of a modified tumor-necrosis factor a receptor gene. Arthritis Rheum 1997; 40: 1662-9
37. Montrucchio G, Lupia E, De Martino A, et al. Nitric oxide mediates angiogenesis induced in vivo by platelet-activating factor and tumor necrosis factor but not by basic fibroblast growth factor. Am J Pathol 1997; 151: 557-63
38. Huizinga TW, Dijkmans BA, van der Velde EA, et al. An open study of pentoxifylline and thalidomide as adjuvant therapy in the treatment of rheumatoid arthritis. Ann Rheum Dis 1996; 55: 833-6
39. Maksymowych WP, Avina-Zubieta A, Luong MH, et al. An open study of pentoxifylline in the treatment of severe refractory rheumatoid arthritis. J Rheumatol 1995; 22: 625-9
40. van der Borne BE, Dijkmans BA, de Rooij HH, et al. Chloroquine and hydroxychloroquine equally affect tumor necrosis factor-alfa, interleukine 6. and interferon-gamma production by peripheral blood mononuclear cells. J Rheumatol 1997; 24: 55-60
41. Moss ML, Jin SL, Milla ME, et al. Cloning a disintegrin metalloproteinuse that processes precursor tumor-necrosis factor-alpha. Nature 1997; 385: 733-6
42. Black RA, Rauch CT, Kozlosky CJ, et al. A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells. Nature 1997; 385: 729-33
43. Williams LM, Gibbons DL, Geargin A, et al. Paradoxical effects of a synthetic metalloproteinase inhibitor that blocks both p55 and p75 TNF receptor shedding and TNF alpha processing in RA synovial membrane cell cultures. J Clin Invest 1996; 97: 2833-41
44. Sander O, den Broeder A, van der Hoogen, et al. 30 months of treatment with a TNFα receptor-fusion protein (TNFR55-IGGI, RO 45-2081) in patients with severe refractory RA [abstract]. Arthritis Rheum 1997; 40 Suppl. 9: s81
45. Sander O, Bock E, Rau R. Safety and efficacy of TNFα receptor-fusion protein (TNFR55-IGGI, RO 45-2081) in patients with RA and liver cirrhosis [abstract]. Arthritis Rheum 1997; 40 Suppl. 9: s81
46. Weisman MH, Markenson J, Wiik A, et al. TNF neutralization does not cause autoantibody changes: the experience with 521 patients enrolled into IV RO 45-2081 trials [abstract]. Arthritis Rheum 1997; 40 Suppl. 9: s81
47. Morgan AW, Hale G, Rebello P, et al. Combination therapy with a TNF antagonist and a CD4 monoclonal antibody in rheumatoid arthritis. A pilol study [abstract]. Arthritis Rheum 1997; 40 Suppl. 9: s81
48. Minghetti PP, Drlica K, Zhang HG, et al. TNFα ribozymes and antisense molecules as potential therapeutic agents for treatment of rheumatoid arthritis [abstract]. Arthritis Rheum 1997; 40 Suppl. 9: s81
49. Maini RN, Breedveld FC, Kalden JR, et al. Low dose methotrexate suppresses anti-globulin responses and potentiates efficacy of a chimeric monoclonal anti-TNFα antibody (cA2) given repeatedly in rheumatoid arthritis [abstract]. Arthritis Rheum 1997; 40 Suppl. 9: s126
50. Weinblatt M, Schiff MH, Baumgartner SW, et al. Long term and phase III treatment of dmard failing rheumatoid arthritis patients with TNF receptor P75 FC fusion protein (TNFR; FC; ENBREL) [abstract]. Arthritis Rheum 1997; 40 Suppl. 9: s126
51. Sander O, Rau R. Long term observation of 80 patients treated with TNFα receptor-fusion protein (TNFR55-IGGI, RO 45-2081) [abstract]. Arthritis Rheum 1997, 40 Suppl. 9: s224
52. Evans J, Yocum DE, Maricic M, et al. Results of an open label. dose-ranging, safety and pharmacokinetic trial of the humanized tumor necrosis factor antibody (HTA) bay 103356, in patients with active rheumatoid arthritis [abstract]. Arthritis Rheum 1997; 40 Suppl. 4: s224